Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02190149 · ClinicalTrials.gov registry record
Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS
A clinical trial, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- 64
- Enrollment target
NCT02190149 is a clinical trial that has completed, run by Baxalta now part of Shire. The registered enrollment target is 64 participants.
The verdict
NCT02190149 has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
Study Summary
This 6-month prospective outcomes study addresses the association between timing of infusion, patient activity levels, and bleeding episodes through patient-reported measurements.
Interventions
- BIOLOGICAL ADVATE (Antihemophilic Factor [Recombinant])
- BIOLOGICAL RIXUBIS (Coagulation Factor IX [Recombinant])
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2014-07-22 |
| Est. Completion | 2016-03-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02190149
The ClinicalTrials.gov registry entry for NCT02190149 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ADVATE (Antihemophilic Factor [Recombinant]) is the first listed.
NCT02190149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02190149 about?
NCT02190149 is a clinical study titled "Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS". This 6-month prospective outcomes study addresses the association between timing of infusion, patient activity levels, and bleeding episodes through patient-reported measurements.
What is the current status of trial NCT02190149?
This trial is currently completed. The enrollment target is 64 participants. The study started on 2014-07-22. Estimated completion is 2016-03-29.
What interventions are being tested in trial NCT02190149?
The interventions under investigation include: ADVATE (Antihemophilic Factor [Recombinant]) (BIOLOGICAL), RIXUBIS (Coagulation Factor IX [Recombinant]) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02190149?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.